Immunomodulatory treatment strategies in multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Immunomodulatory treatment strategies in multiple sclerosis.

Immunomodulatory treatment strategies in multiple sclerosis.

http://www.wikidata.org/entity/Q37419041

about

Perspectives on the use of multiple sclerosis risk genes for prediction Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study.Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis Development of small-molecule therapies for autoimmune diseases.Ten years of proteomics in multiple sclerosis.Being Kind to Your Future Self: Probability Discounting of Health Decision-Making.Exacerbation history is associated with medication and appointment adherence in MS.IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9.

P2860

Q34098864-DA370849-ADD1-45E8-A651-C1D4C9C207C7 Q34713974-2FFEE6FE-9942-438A-B1D0-BD3921F8E817 Q34997074-0A4622B9-9E64-4DA4-9AEA-6FC83C382A83 Q35689857-5330E066-DF94-42F6-B1D4-73BC704CE260 Q37730104-1E7D957A-4214-4FDA-A4FD-EF9BE6EF5907 Q38171465-01FB8696-8D12-4FD2-9EC6-7CB1B70C913C Q38931794-550A0CFE-AEDF-4EB6-BE70-C8CF7D5558D8 Q39790686-6BCF4029-074B-47D3-885A-55602EA9DEBA Q40781908-64F6254F-4F6F-47E3-AF0A-DE27AAEADC82

P2860

Immunomodulatory treatment strategies in multiple sclerosis.

http://www.wikidata.org/entity/Q37419041

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunomodulatory treatment strategies in multiple sclerosis.

@en

Immunomodulatory treatment strategies in multiple sclerosis.

@nl

type

label

Immunomodulatory treatment strategies in multiple sclerosis.

@en

Immunomodulatory treatment strategies in multiple sclerosis.

@nl

prefLabel

Immunomodulatory treatment strategies in multiple sclerosis.

@en

Immunomodulatory treatment strategies in multiple sclerosis.

@nl

P1433

Q37419041-E3B8208C-01F3-4B7B-8936-B2590F7BF2F2

P1476

Q37419041-2905725F-D396-4A25-925B-E6DCB8AF850F

P2093

Q37419041-5ED89327-F769-485F-B320-194A5CA3B2AA

P2860

Q37419041-14709D67-E2A2-449F-92A1-6F7B62C8018B

Q37419041-175EADAC-6DB0-451A-A4E5-E310428C8588

Q37419041-1BB669C8-C993-4762-AB51-8DCE3C3AE983

Q37419041-50D6C0E7-630D-4658-8820-C65BF3AE65B7

Q37419041-5D4A0C8D-1941-4DBD-9FB5-34292F088EB0

Q37419041-7BC82E38-75E2-45D0-8460-7DFED108D9F7

Q37419041-7C821859-6D41-493B-ACC0-E6706B45E3E1

Q37419041-9876A13A-A214-4405-B8BD-D98528225D99

Q37419041-DB4DC733-FD6E-4149-927A-AC1F25F74EEB

Q37419041-E1EF63F6-853C-40DD-B3CB-AAAE22B9924E

P2888

Q37419041-D67DCD9A-BD62-4C25-B483-B266E7F8B9AF

P304

Q37419041-CEECCDAA-9CE4-4523-BEF6-73E26BF2C1E6

P31

Q37419041-62D2A811-5271-4C73-8CF6-BA0DD283B4D5

P356

Q37419041-73DC0032-1E75-47CB-BD48-D3DA2E92B8A8

P478

Q37419041-31637A9D-9C2A-4B31-AFA8-FE8AD335E2FE

P50

Q37419041-67CFDAB7-9440-4D17-B900-F3B817833533

Q37419041-8F2B799C-8A80-4746-866E-6BD3D82822BB

Q37419041-E5DF880D-894C-4456-9DC7-42C230EFDEBA

P577

Q37419041-830549A6-3A43-4CAD-978F-B167DCC2373E

P698

Q37419041-54E28A67-4F76-4DD5-B4BF-EACB2A846FF4

P921

Q37419041-E742F222-7E44-498D-A2FE-E458F7AE9ECF

P356

S00415-008-6004-Z

P1433

Journal of Neurology

P1476

Immunomodulatory treatment strategies in multiple sclerosis.

@en

P2093

Verena I Leussink

http://www.w3.org/2001/XMLSchema#string

P2860

Optic neuritis: A population-based study in Olrnsted County, Minnesota

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.

Matrix metalloproteinases in inflammatory demyelination: targets for treatment.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.

Multisequence MRI in clinically isolated syndromes and the early development of MS.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

P2888

s00415-008-6004-z

P304

15-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-008-6004-Z

http://www.w3.org/2001/XMLSchema#string

P478

255 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P50

Bernd C Kieseier

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19300955

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis